3 hours UBS Group Begins Coverage on Nurix Therapeutics (NASDAQ:NRIX)MarketBeat
UBS Group assumed coverage on Nurix Therapeutics in a report on Thursday. They set a “buy” rating and a $35.00 target price on the stock.
XUBS Group assumed coverage on Nurix Therapeutics in a report on Thursday. They set a “buy” rating and a $35.00 target price on the stock.
X